A Phase II Study of AUY922, a Novel HSP Inhibitor, in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Failed to or Intolerance of Imatinib and Sunitinib Therapy

Trial Profile

A Phase II Study of AUY922, a Novel HSP Inhibitor, in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Failed to or Intolerance of Imatinib and Sunitinib Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2013

At a glance

  • Drugs Luminespib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Sep 2013 Planned end date changed from 1 Jul 2019 to 1 Oct 2019 as reported by ClinicalTrials.gov.
    • 12 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top